{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T05:24:04Z","timestamp":1759814644928,"version":"3.40.5"},"reference-count":28,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T00:00:00Z","timestamp":1670889600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Kyowa Kirin Co., Ltd."}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>The dosage of evocalcet required to control serum parathyroid hormone (PTH) levels varies among secondary hyperparathyroidism (SHPT) patients. This post hoc analysis evaluated the dose-dependent efficacy of evocalcet on serum intact PTH (iPTH) levels, corrected calcium (Ca) and phosphate (P) levels, and safety, in an evaluation period (week 28 to week 30) by stratifying the previous phase 3 data with the final evocalcet dosages (low 1\u20132 mg [131 patients], medium 3\u20134 mg [90 patients], high 5\u20138 mg [92 patients]), and identified pre-treatment patient characteristics predicting the use of higher final evocalcet dosages via univariate and multivariate logistic regression models. At the end of the study at week 30, the median serum iPTH level was higher and the achievement ratio for the target range of Japanese Society for Dialysis Therapy (60\u2013240 pg\/mL) was lower in the final high-dose subgroup (216 pg\/mL and 58%, respectively) than in the other subgroups (low: 149 pg\/mL and 79%; medium: 149 pg\/mL and 73%, respectively). Among the three subgroups, the mean serum corrected Ca and P levels demonstrated similar trends, and similar ratio of patients achieved the target range (corrected Ca, 8.4\u201310 mg\/dL; P, 3.5\u20136.0 mg\/dL) from week 28 to week 30. No dose-dependent safety concerns were identified. Younger age, prior cinacalcet use, higher serum levels of iPTH and corrected Ca, procollagen type 1 N-terminal propeptide, intact fibroblast growth factor-23, and larger maximum parathyroid gland volume were significantly associated with final high-dose evocalcet (<jats:italic>p<\/jats:italic> &lt; 0.05 in all cases). Patients requiring final high-dose evocalcet had pre-treatment characteristics indicating severe SHPT, leading to a lower final achievement rate for the target PTH levels of Japanese Society for Dialysis Therapy. Therefore, the early initiation of evocalcet treatment for SHPT is critical.<\/jats:p>\n<jats:p><jats:bold>Trial registration<\/jats:bold>: This trial was registered as follows: ClinicalTrials.gov: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02549391\" xlink:type=\"simple\">NCT02549391<\/jats:ext-link> and JAPIC: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/rctportal.niph.go.jp\/en\/detail?trial_id=JapicCTI-153013\" xlink:type=\"simple\">JapicCTI-153013<\/jats:ext-link>.<\/jats:p>","DOI":"10.1371\/journal.pone.0279078","type":"journal-article","created":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T18:59:05Z","timestamp":1670957945000},"page":"e0279078","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Predictive factors requiring high-dose evocalcet in hemodialysis patients with secondary hyperparathyroidism"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8012-7172","authenticated-orcid":true,"given":"Masanori","family":"Tokumoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Tokunaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7717-8945","authenticated-orcid":true,"given":"Shinji","family":"Asada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Endo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4127-7500","authenticated-orcid":true,"given":"Noriaki","family":"Kurita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Fukagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadao","family":"Akizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2022,12,13]]},"reference":[{"key":"pone.0279078.ref001","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2215\/CJN.06040710","article-title":"Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options","volume":"6","author":"J Cunningham","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"pone.0279078.ref002","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s10157-011-0502-5","article-title":"Diseases of the parathyroid gland in chronic kidney disease","volume":"15","author":"H Komaba","year":"2011","journal-title":"Clin Exp Nephrol"},{"key":"pone.0279078.ref003","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.kint.2017.04.006","article-title":"Executive summary of the 2017 KDIGO Chronic Kidney Disease\u2013Mineral and Bone Disorder (CKD-MBD) Guideline Update: what\u2019s changed and why it matters","volume":"92","author":"M Ketteler","year":"2017","journal-title":"Kidney Int"},{"key":"pone.0279078.ref004","doi-asserted-by":"crossref","first-page":"e0201537","DOI":"10.1371\/journal.pone.0201537","article-title":"Phosphate control in reducing FGF23 levels in hemodialysis patients","volume":"13","author":"C Rodelo-Haad","year":"2018","journal-title":"PLoS One"},{"key":"pone.0279078.ref005","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","article-title":"Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO).","volume":"69","author":"S Moe","year":"2006","journal-title":"Kidney Int"},{"key":"pone.0279078.ref006","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.atherosclerosis.2018.08.046","article-title":"CKD, arterial calcification, atherosclerosis and bone health: inter-relationships and controversies","volume":"278","author":"AB Reiss","year":"2018","journal-title":"Atherosclerosis"},{"key":"pone.0279078.ref007","doi-asserted-by":"crossref","first-page":"98","DOI":"10.2215\/CJN.12941213","article-title":"Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study","volume":"10","author":"F Tentori","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"pone.0279078.ref008","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/ckj\/sfx125","article-title":"Old and new calcimimetics for treatment of secondary hyperparathyroidism: impact on biochemical and relevant clinical outcomes.","volume":"11","author":"L Pereira","year":"2018","journal-title":"Clin Kidney J."},{"key":"pone.0279078.ref009","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s40261-018-0687-4","article-title":"Evocalcet Study Group. Pharmacokinetics, pharmacodynamics, and safety of the novel calcimimetic agent evocalcet in healthy Japanese subjects: first-in-human phase I study","volume":"38","author":"T Akizawa","year":"2018","journal-title":"Clin Drug Investig"},{"key":"pone.0279078.ref010","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/1744-9987.13434","article-title":"Evocalcet: a new oral calcimimetic for dialysis patients with secondary hyperparathyroidism.","volume":"24","author":"T Akizawa","year":"2019","journal-title":"Ther Apher Dial"},{"key":"pone.0279078.ref011","doi-asserted-by":"crossref","first-page":"e0204896","DOI":"10.1371\/journal.pone.0204896","article-title":"Phase 2b study of evocalcet (KHK7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: a randomized, double-blind, placebo-controlled, dose-finding study","volume":"13","author":"Evocalcet Study Group","year":"2018","journal-title":"PLoS One."},{"key":"pone.0279078.ref012","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.kint.2018.05.013","article-title":"Akizawa T; Evocalcet study group. Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism","volume":"94","author":"M Fukagawa","year":"2018","journal-title":"Kidney Int"},{"key":"pone.0279078.ref013","doi-asserted-by":"crossref","first-page":"e0195316","DOI":"10.1371\/journal.pone.0195316","article-title":"A novel calcimimetic agent, evocalcet (MT-4580\/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro","volume":"13","author":"T Kawata","year":"2018","journal-title":"PLoS One"},{"key":"pone.0279078.ref014","first-page":"101","article-title":"Pharmacokinetics of evocalcet in secondary hyperparathyroidism patients receiving hemodialysis: first-in-patient clinical trial in Japan","volume":"10","author":"T Shigematsu","year":"2018","journal-title":"Clin Pharmacol"},{"key":"pone.0279078.ref015","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s10157-018-1635-6","article-title":"Akizawa T; Evocalcet Study Group. Pharmacodynamics of evocalcet for secondary hyperparathyroidism in Japanese hemodialysis patients","volume":"23","author":"T Shigematsu","year":"2019","journal-title":"Clin Exp Nephrol"},{"key":"pone.0279078.ref016","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s10157-019-01692-y","article-title":"Akizawa T; Evocalcet Study Group. Efficacy and safety of evocalcet in Japanese peritoneal dialysis patients","volume":"23","author":"K Tsuruya","year":"2019","journal-title":"Clin Exp Nephrol"},{"key":"pone.0279078.ref017","doi-asserted-by":"crossref","first-page":"6410","DOI":"10.1038\/s41598-019-42017-z","article-title":"Evocalcet Study Group. Long-term efficacy and safety of evocalcet in Japanese patients with secondary hyperparathyroidism receiving hemodialysis","volume":"9","author":"K Yokoyama","year":"2019","journal-title":"Sci Rep"},{"key":"pone.0279078.ref018","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1111\/j.1523-1755.2000.00370.x","article-title":"Association of decreased calcium-sensing receptor expression with proliferation of parathyroid cells in secondary hyperparathyroidism","volume":"58","author":"S Yano","year":"2000","journal-title":"Kidney Int"},{"key":"pone.0279078.ref019","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/1744-9987.12058","article-title":"Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder","volume":"17","author":"M Fukagawa","year":"2013","journal-title":"Ther Apher Dial"},{"key":"pone.0279078.ref020","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1093\/ndt\/14.10.2398","article-title":"The PTH-calcium curve and the set point of calcium in primary and secondary hyperparathyroidism","volume":"14","author":"F Malberti","year":"1999","journal-title":"Nephrol Dial Transplant"},{"key":"pone.0279078.ref021","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1038\/sj.ki.5001754","article-title":"Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study","volume":"70","author":"M Jadoul","year":"2006","journal-title":"Kidney Int"},{"key":"pone.0279078.ref022","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1056\/NEJM199507203330307","article-title":"Renal osteodystrophy","volume":"333","author":"KA Hruska","year":"1995","journal-title":"N Engl J Med"},{"key":"pone.0279078.ref023","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0008-6363(97)00194-6","article-title":"Cardiovascular actions of parathyroid hormone and parathyroid hormone-related peptide","volume":"37","author":"KD Schl\u00fcter","year":"1998","journal-title":"Cardiovasc Res"},{"key":"pone.0279078.ref024","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/ndt\/gfr447","article-title":"Parathyroid hormone and phosphorus overload in uremia: impact on cardiovascular system.","volume":"27","author":"MR Cust\u00f3dio","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"pone.0279078.ref025","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1093\/ndt\/gfv421","article-title":"Induction of cardiac FGF23\/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease","volume":"31","author":"M Leifheit-Nestler","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"pone.0279078.ref026","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.cmet.2015.11.003","article-title":"PTH\/PTHrP receptor mediates cachexia in models of kidney failure and cancer","volume":"23","author":"S Kir","year":"2016","journal-title":"Cell Metab"},{"key":"pone.0279078.ref027","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/hdi.12315","article-title":"Phosphate binder pill burden, patient-reported non-adherence, and mineral bone disorder markers","volume":"20","author":"RB Fissell","year":"2016","journal-title":"Findings from the DOPPS. Hemodial Int"},{"key":"pone.0279078.ref028","doi-asserted-by":"crossref","first-page":"c109","DOI":"10.1159\/000319882","article-title":"Cinacalcet treatment for secondary hyperparathyroidism in dialysis patients: an observational study in routine clinical practice","volume":"118","author":"J Bover","year":"2011","journal-title":"Nephron Clin Pract"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0279078","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T18:59:41Z","timestamp":1670957981000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0279078"}},"subtitle":[],"editor":[{"given":"Gianpaolo","family":"Reboldi","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,12,13]]},"references-count":28,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0279078","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2022,12,13]]}}}